Current state and future prospect of chimeric antigen receptor (CAR) T-cell therapy for glioblastoma

Qin Zhang

doi:10.1117/12.3013219

8 January 2024 Current state and future prospect of chimeric antigen receptor (CAR) T-cell therapy for glioblastoma

Qin Zhang

Proceedings Volume 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023); 1292441 (2024) https://doi.org/10.1117/12.3013219
Event: 3rd International Conference on Biological Engineering and Medical Science (ICBioMed2023), 2023, ONLINE, United Kingdom

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has brought giant advancement in hematological malignances treatment, which arises interests of applying the technology in solid tumors. Glioblastoma, a malignant brain tumor with high recurrence rate and low survival rate, has threaten considerable people’s lives and caused heavy social burdens. The efficacy of traditional treatments in glioblastoma turns out to be limited, and immunotherapies such as CAR T-cell therapy might blaze a novel trail to achieve better clinical response. Here, the author reviewed the development history and potential mechanisms of CAR T-cell therapy, summarizing related outcomes from preclinical and clinical research including multiple tumor antigens targeted by CARs, feasibility and potential efficacy of this immunotherapy in glioblastoma. Moreover, myriad difficulties that this treatment now encounters as well as their corresponding solutions were also discussed. At present, it is evident that this immunotherapy has the potential to be applied in glioblastoma treatment, but more research is expected in the future in order to unravel the unknowns and improve therapeutic strategies for glioblastoma.

(2024) Published by SPIE. Downloading of the abstract is permitted for personal use only.

Citation Download Citation

Qin Zhang "Current state and future prospect of chimeric antigen receptor (CAR) T-cell therapy for glioblastoma", Proc. SPIE 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023), 1292441 (8 January 2024); https://doi.org/10.1117/12.3013219

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
6 PAGES

DOWNLOAD PAPER SAVE TO MY LIBRARY

GET CITATION

RIGHTS & PERMISSIONS

Get copyright permission Get copyright permission on Copyright Marketplace

KEYWORDS

Tumors

Clinical trials

Cancer

Solids

Radiotherapy

Brain

Tissues

Show All Keywords

Keywords/Phrases

Search In:

Publication Years